Brokerages expect Regulus Therapeutics Inc (NASDAQ:RGLS) to report $7.01 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Regulus Therapeutics’ earnings. The lowest sales estimate is $7.00 million and the highest is $7.02 million. Regulus Therapeutics reported sales of $20,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 34,950%. The business is expected to announce its next earnings report on Wednesday, March 6th.

On average, analysts expect that Regulus Therapeutics will report full year sales of $7.09 million for the current fiscal year, with estimates ranging from $7.07 million to $7.10 million. For the next year, analysts expect that the firm will report sales of $5.09 million, with estimates ranging from $70,000.00 to $10.10 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Regulus Therapeutics.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.25) by $0.07. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 75,823.62% and a negative return on equity of 311.60%.

A number of research analysts have issued reports on the stock. Zacks Investment Research cut shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Wedbush set a $2.00 price target on shares of Regulus Therapeutics and gave the stock a “hold” rating in a report on Tuesday, November 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 6th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $1.30.

In related news, Director Stelios Papadopoulos purchased 50,000 shares of the firm’s stock in a transaction on Saturday, December 28th. The stock was acquired at an average price of $1.09 per share, with a total value of $54,500.00. Following the completion of the acquisition, the director now owns 835,073 shares in the company, valued at approximately $910,229.57. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders acquired 173,501 shares of company stock valued at $177,420. Corporate insiders own 5.40% of the company’s stock.

A hedge fund recently raised its stake in Regulus Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) by 396.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 595,501 shares of the biopharmaceutical company’s stock after purchasing an additional 475,512 shares during the period. Renaissance Technologies LLC owned approximately 6.82% of Regulus Therapeutics worth $118,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Shares of NASDAQ RGLS traded up $0.03 during midday trading on Friday, reaching $1.13. The company had a trading volume of 97,539 shares, compared to its average volume of 327,486. The stock has a market cap of $10.85 million, a P/E ratio of -0.10 and a beta of 2.12. Regulus Therapeutics has a 1 year low of $0.80 and a 1 year high of $17.28.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Further Reading: What Factors Can Affect Return on Equity?

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with's FREE daily email newsletter.